Paratek Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Paratek Pharmaceuticals's estimated annual revenue is currently $17.1M per year.
- Paratek Pharmaceuticals received $50.0M in venture funding in January 2018.
- Paratek Pharmaceuticals's estimated revenue per employee is $65,084
- Paratek Pharmaceuticals's total funding is $133M.
Employee Data
- Paratek Pharmaceuticals has 263 Employees.
- Paratek Pharmaceuticals grew their employee count by -12% last year.
Paratek Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder | Reveal Email/Phone |
2 | Chief Development and Regulatory Office | Reveal Email/Phone |
3 | Executive Director, National Sales Government Accounts at Paratek Pharmaceuticals | Reveal Email/Phone |
4 | CEO | Reveal Email/Phone |
5 | President, COO & CMO | Reveal Email/Phone |
6 | VP, Finance | Reveal Email/Phone |
7 | VP, Head Digital Information and Strategic Solutions | Reveal Email/Phone |
8 | Head Biothreat Research | Reveal Email/Phone |
9 | VP Medical And Scientific Strategy | Reveal Email/Phone |
10 | VP, Market Access, Trade and Government Affairs | Reveal Email/Phone |
Paratek Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Paratek Pharmaceuticals?
Paratek Pharmaceuticals (NASDAQ: PRTK) is a biopharmaceutical company that develops transformative solutions for patients, both in and out of the hospital, with diseases that are not responsive to current treatments. We focus on drugs that target infectious disease and other difficult to treat conditions. Our lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethycyclines, with broad spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is being developed as a once daily, oral and intravenous, empiric monotherapy for community acquired bacterial infections, particularly when antibiotic resistance is of concern. The Food and Drug Administration (FDA) granted omadacycline a Qualified Infectious Disease Product (QIDP) designation and completed two special protocol assessments for its Phase 3 clinical trial program.
keywords:Biotechnology,Healthcare,Mobile,Pharmaceuticals
$133M
Total Funding
263
Number of Employees
$17.1M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Paratek Pharmaceuticals News
Zacks: Analysts Expect Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) to Announce -$0.35 Earnings Per Share. Posted by admin on Apr 21st, 2022.
PRTK gets a Bearish score from InvestorsObserver Stock Sentiment Indicator. Sentiment Score - ,bearish. Paratek Pharmaceuticals Inc has a...
Do Analysts Expect Paratek Pharmaceuticals Inc (PRTK) Stock to Rise After It Is Lower By -14.42% in a Month? Thursday, April 14, 2022 10:45 AM |...
- Oral-only dosing for the Treatment of CABP Expands the Commercial Opportunity for Primary Care Promotion - Primary Care Market Opportunity for CABP Estimated at Approximately $1.5 Billion BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-sta ...
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) stock has been on a recent steady downtrend, causing some concern for shareholders.
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $233M | 265 | 32% | $257M |
#2 | $64.9M | 266 | 24% | $9.1M |
#3 | $15M | 266 | 6% | N/A |
#4 | $42.7M | 268 | 6% | N/A |
#5 | $60.7M | 269 | 7% | $3.5M |
Paratek Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2002-04-11 | $30.2M | D | Article | |
| 2004-10-01 | $13.7M | Undisclosed | Bayer | Article |
| 2007-10-26 | $22.0M | H | Article | |
| 2008-04-17 | $40.0M | Undisclosed | Aisling Capital, D.E. Shaw Group | Article |
| 2014-07-21 | $93.0M | Undisclosed | Article | |
| 2015-04-29 | $69.0M | Undisclosed | Leerink Partners | Article |
| 2018-01-19 | $50.0M | Undisclosed | BTIG, LLC | Article |